Combining cutting edge computational and experimental methods for targeting KRAS mutations in non-small cell lung cancer

Introduction Historically, KRAS mutations have been notoriously difficult to target despite their status as the most commonly mutated oncogene in the RAS gene family. However, pioneering work by Shokat and colleagues has led to the discovery of KRAS G12C-GDP mutant specific inhibitors, with two such inhibitors adagrasib and sotorasib now FDA approved for treatment of non-small cell lung cancer (NSCLC). Unfortunately, despite FDA approval, several patients did not achieve full treatment response. Further drug discovery is urgently needed to identify compounds capable of synergizing with available KRAS G12C inhibitors to prevent drug resistance, pan-KRAS inhibitors capable of binding multiple KRAS mutations, and KRAS-GTP inhibitors.Areas covered This review encompasses the development of the first KRAS G12C inhibitors through rational drug design, to recent advances in precision oncology utilizing artificial intelligence (AI) to identify compounds capable of targeting KRAS G12C, D, and V in-dividually, as well as pan-KRAS and SOS1 inhibitors. The literature search was made using PubMed and Google Scholar with keywords”KRAS G12C inhibitors,””NSCLC,””pan-KRAS inhibitors,””AI,” and”drug discovery” from 2013 to 2025.Expert opinion Recent studies support the view that integration of AI algorithms with experimental methods is a key aspect in stream-lining the drug discovery process and identifying molecules with greater structural diversity, less off target effects than traditional screening methods. Furthermore, the authors believe that AI will eventually become standardized in drug discovery and existing pipelines specific to KRAS mutant inhibitor design will be expanded for additional KRAS mutations as well as other aggressive driver oncogenes across multiple cancers.